Key points are not available for this paper at this time.
The model provides an evidence-based, accessible way of understanding diverse corporate political strategies. It should enable public health actors and officials to preempt these strategies and develop realistic assessments of the industry's claims.
Ulucanlar et al. (Tue,) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: